|
|
|
|
|
|
| Advertisement |
 |
|
|
| Advertisement |
2017 Real-World Evidence Benchmark Survey
Deloitte's 2017 Real-World Evidence Benchmark Survey shows that life sciences companies are making some progress in using RWE but still have opportunities to expand applications across the value chain, consider new channels to access RWD, and improve their overall capabilities. Explore this research Today!
|
|
| Regulatory Affairs |
 |
|
Bracing for Drug Tracing Mandate
|
Pilot study affirms the value of a standards-based solution for prescription drug traceability—and the need to start now to meet compliance deadlines for the Drug Supply Chain Security Act.
... /Read more/ |
|
|
| Advertisement |
Winning the RAT race: A new Center of Excellence to drive development of regenerative medicines
Live Webinar: Tuesday, May 2 at 11:00am EDT
Register now
|
|
| Regulatory Affairs |
|
|
The EFPIA Disclosure Experience: An Update
|
Nine months on from the 2016 EFPIA Disclosure Code deadline — requiring all member companies to publish data concerning their transfer-of-value transactions to HCPs — EFPIA's Andrew Powrie-Smith offered an update on media and industry responses.
... /Read more/ |
|
|
|
| Advertisement |
Winning the RAT race: A new Center of Excellence to drive development of regenerative medicines
Live Webinar: Tuesday, May 2 at 11:00am EDT
Register now
|
|
|
|
|
|
|
|
